New government drug repurposing programs: Opportunities and uncertainties.

Liddicoat, Johnathon; Hamidzadeh, Ashleigh; Liddell, Kathleen; Schito, Marco; Simon, David; Aboy, Mateo; Minssen, Timo

Liddicoat, Johnathon; Hamidzadeh, Ashleigh; Liddell, Kathleen; Schito, Marco; Simon, David; Aboy, Mateo; Minssen, Timo.

Afiliação

Liddicoat J; Dickson Poon School of Law, King's College London, WC2R 2LS London, UK.
Hamidzadeh A; Dickson Poon School of Law, King's College London, WC2R 2LS London, UK.
Liddell K; Faculty of Law, University of Cambridge, CB3 9DZ Cambridge, UK.
Schito M; James E. Rogers College of Law, University of Arizona, Tucson, AZ 85721, USA.
Simon D; School of Law, Northeastern University, Boston, MA 02115, USA.
Aboy M; Faculty of Law, University of Cambridge, CB3 9DZ Cambridge, UK.
Minssen T; Faculty of Law, University of Copenhagen, DK-2300 Copenhagen, Denmark.

Sci Transl Med ; 16(753): eadl0998, 2024 Jun 26.

Article em En | MEDLINE | ID: mdl-38924430

ABSTRACT

ABSTRACT

Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.

Assuntos

Reposicionamento de Medicamentos; Humanos; Estados Unidos; Europa (Continente); Incerteza; Propriedade Intelectual; Programas Governamentais/economia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reposicionamento de Medicamentos Limite: Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google